| Revenue growth | FY26 consolidated revenue rose 27.5% YoY; Q4 growth at 15.8%. |
|---|---|
| Margins | FY27 EBITDA margin guided at 21-22%, up from previous levels. |
| Demand visibility | Strong in India and Europe; US respiratory recovery expected in FY27. |
| Management confidence | High, focused on innovative oncology pipeline and 'gross debt-free' milestone. |
Growth
Consolidated revenue grew 15.8% YoY for Q4 and 27.5% for FY26, driven by a landmark $700M AbbVie deal.
Outlook
FY27 guidance targets ₹17,000-18,000cr revenue with 21-22% EBITDA margins and major oncology launches.
Risks
US market volatility, ongoing legal settlements, and geopolitical disruptions affecting supply chains in the MEA region remain key hurdles.
Earnings Call filed with BSE, NSE: GLENMARK. Summary written with AI assistance from the document.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,282.30
- Market cap
- ₹64,412 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 35.8×Sector 47.4×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 20.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Business Update
Glenmark Pharmaceuticals received an Establishment Inspection Report from the U.S. FDA for its Goa facility, which has been assigned a Voluntary Action Indicated status.
Glenmark Pharmaceuticals Annual General Meeting
Glenmark Pharmaceuticals held its 48th Annual General Meeting on September 11, 2026. The company submitted the proceedings, Scrutinizer’s Report, and voting results to the exchanges.
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched RYALTRIS® nasal spray in Brazil to treat moderate to severe allergic rhinitis, expanding its global respiratory product footprint in Latin America.
Glenmark Pharmaceuticals Credit Rating
India Ratings upgraded Glenmark Pharmaceuticals' long-term bank loans to 'IND AA+' and affirmed short-term ratings at 'IND A1+'.
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals Inc., USA has launched Calcium Gluconate Injection USP in various dosages. This launch expands the company's injectable portfolio and presence in the U.S. hospital market.
Glenmark Pharmaceuticals Business Update
Glenmark Pharmaceuticals received U.S. FDA approval for its Fluticasone Propionate Nasal Spray. The product will be distributed in the U.S. market.